NHS Wales has signed a memorandum of understanding (MoU) with Illumina to expand an earlier partnership focusing on lung ...

Shares of Illumina (ILMN) fell 6% post-market Monday after the company lowered its fiscal 2024 revenue guidance. Read more ...

Illumina to present updates on several key innovations in whole-genome sequencing, proteomics, and single-cell technology at ASHG meeting: San Diego Monday, November 4, 2024, 17:0 ...

Illumina is a prominent entity in the genomic sequencing market, providing advanced DNA sequencing platforms and associated ...

Here is a breakdown of the information Illumina presented to its investors. Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, serving the research, clinical, and ...

Illumina, a United States-headquartered company specializing in DNA sequencing and array-based technologies, is showcasing ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing ...

The Human Genome Project described the first (almost) complete reference genome, but it didn’t say much about human variation ...